Pyrilutamide (KX-826) is a new hair loss treatment being developed by Kintor Pharmaceuticals. It has entered phase III clinical trials in China and the US. These trials will determine whether it is effective in treating androgenetic alopecia.
Kintor Pharmaceuticals is a clinical stage company discovering medicine for androgen receptor-related diseases where no effective treatments exist. The company has several promising drugs in development including Proxalutamide, KX-826 and GT90001.
Buy pyrilutamide online
Buy pyrilutamide Europe (KX-826) is a potent androgen receptor antagonist in development for the treatment of male pattern baldness. The compound is undergoing phase II clinical trials in the US and China for the condition.It is a first-in-class topical anti-androgen with superior efficacy to existing medications such as finasteride or dutasteride.
It is a member of the sulphonamide family and works by blocking testosterone and DHT from binding with androgen receptors in the hair follicles, which blocks hair growth.It is the most powerful androgen receptor blocker available, with a higher binding affinity than androstiostatin.
The drug is developed by Kintor Pharmaceuticals, a biotechnology company that discovers and develops small molecule therapeutics to treat androgen receptor-related diseases including prostate, breast, blood, liver cancer, and baldness. GlobalData’s Pyrilutamide LoA Report tracks drug-specific PTSR and indication benchmarks based on 18 years of historical drug development data, as well as providing a clear view of the path to market for the compound.
Buy pyrilutamide in the UK
Pyrilutamide (KX826) is an androgen receptor antagonist being developed by Kintor Pharmaceuticals for the treatment of androgenic alopecia.It is currently in phase II clinical trials in the US and China for this indication.
It is a small molecule and has similar structure as the FDA approved anti-androgen RU58841.It is a highly potent anti-androgen with high binding affinity to DHT receptor.It has shown a promising efficacy in androgenetic alopecia in previous clinical trials and has less side effects than current treatment options.
Kintor Pharmaceutical Ltd is a development stage drug company focused on discovering and developing novel small molecule therapeutics targeting cancer and other androgen receptor related diseases. The company is developing the anti-androgen proxalutamide (GT0918), the mTOR inhibitor Destorsertib (GT1708F), and ALK-1 inhibitor GT0486A. It is also exploring other compounds including pyrilutamide (KX-826).
Buy pyrilutamide in Germany
Buy pyrilutamide in Europe (development code KX-826) is an antiandrogen in development for androgenic alopecia. It works by blocking DHT and testosterone from binding to androgen receptors in hair follicles. It has completed phase II clinical trials in male and female patients with androgenetic alopecia.Kintor Pharmaceuticals is also developing a topical version of the drug, Ru58841, for acne vulgaris.
According to GlobalData’s PTSR score analysis, pyrilutamide has a promising chance of advancing into phase 3 for androgenic alopecia.
However, the drug will need to perform better than finasteride or RU58841 in phase 2 in order to meet its clinical goals.
Founded in 2021, Kintor Pharmaceutical is a biotechnology company focusing on androgen receptor-related disease areas where no effective treatments exist. The company develops and markets innovative small molecules and biological therapeutics. It carts products to clients across Taiwan, China, Hong Kong, the US, and Brazil. The company has a variety of drugs in development, including Proxalutamide, Pyrilutamide, ALK-1 inhibitor GT90001, Destorsertib, and others.
Buy pyrilutamide in France
Pyrilutamide (KX-826) is a new chemical developed by Kintor Pharmaceuticals for the treatment of androgenetic alopecia.
It has been shown to be effective in clinical trials conducted by the company.
It is expected to enter phase III clinical trials in 2022.
These will be randomized,double-blind studies with a sample size of 416 and will last for 24 weeks.
PyriPure is a pure pyrilutamide solution in a propylene glycol and ethanol vehicle. It is >99% pure and can be analyzed by a 3rd party for purity confirmation. It comes with a calibrated dropper.
According to GlobalData’s Pharma Intelligence Centre, there are 20 assets in development for androgenetic alopecia.
These range from a month-long injection of minoxidil, developed by Cosmo Pharmaceuticals,
to GT-20029 and KX-826, two antiandrogen compounds being developed by Kintor Pharmaceuticals.
